The failure of animal models to predict therapeutic responses in humans is a major problem
that also brings into question their use for basic research. Organ-on-a-chip (organ chip) …

Senescence is a cellular response to a variety of stress signals that is characterized by a
stable withdrawal from the cell cycle and major changes in cell morphology and physiology …

Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …

Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

Abstract Cyclin-dependent kinase 4 (CDK4) and CDK6 are critical mediators of cellular
transition into S phase and are important for the initiation, growth and survival of many …

The development of neoplasia involves a complex and continuous interplay between
malignantly transformed cells and the tumour microenvironment (TME). Cancer …

Biomedical research is undergoing a paradigm shift towards approaches centred on human
disease models owing to the notoriously high failure rates of the current drug development …

Dysregulated cell division, which leads to aberrant cell proliferation, is one of the key
hallmarks of cancer. Therefore, therapeutic targets that block cell division would be effective …

Aberrancy in cell cycle progression is one of the fundamental mechanisms underlying
tumorigenesis, making regulators of the cell cycle machinery rational anticancer therapeutic …

Abstract 'Immune checkpoint blockade'for cancer describes the use of therapeutic antibodies
that disrupt negative immune regulatory checkpoints and unleash pre-existing antitumour …